BioPorto Submits FDA Pre-Submission for Adult NGAL Diagnostic Program

BioPorto A/S has officially submitted its pre-submission package to the U.S. Food and Drug Administration (FDA) for its adult urine NGAL program. This regulatory milestone follows a successful analysis of the EPACRA AKI study, which provided critical data for determining clinical cut-off levels. The diagnostic program focuses on identifying Acute Kidney Injury (AKI) through the company's proprietary NGAL testing technology. This submission represents a significant step forward in BioPorto's strategy to secure market clearance and expand its footprint in the United States. By advancing through the FDA's regulatory framework, the company demonstrates tangible progress in its clinical development pipeline. Investors view this move as a positive indicator of the company's ability to meet rigorous regulatory standards. The formal request sets the stage for further dialogue with the FDA regarding the commercialization of the NGAL test for adult patients.